In vitro cytokine profile in childhood alopecia areata and the immunomodulatory effects of AS-101

Clinical and Experimental Dermatology

Volumn 30, Issue 4, 2005, Pages 432-434

  Shohat, M ^a   Mimouni, Daniel ^a,b   Ben Amitai, D ^a,b   Sredni, B ^c   Sredni, D ^c   Shohat, B ^a,b   David, M ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c BAR ILAN UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM TRICHLORO(DIOXYETHYLENE O,O')TELLURATE; CYTOKINE; GAMMA INTERFERON; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 5; INTERLEUKIN 6;

ADOLESCENT; ALOPECIA; ALOPECIA AREATA; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ADOLESCENT; ALOPECIA AREATA; AUTOIMMUNE DISEASES; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; CYTOKINES; ETHYLENES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALE; PHYTOHEMAGGLUTININS;

EID: 20644448819     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2005.01817.x     Document Type: Article

References (9)

1. Teraki Y, Imanishi K, Shiohara T. Cytokines in alopecia areata: contrasting cytokine profiles in localized form and extensive form (alopecia universalis). Acta Derm Venerol 1996; 76: 421-3.
2. Gupta AK, Ellis CN, Cooper KD et al Oral cyclosporine for the treatment of alopecia areata. A clinical and immunohistochemical analysis. J Am Acad Dermatol 1990; 22: 242-50.
3. Shohat B, Kozenisky L, David M et al. Effect of UVB and AS101 on interleukin-2 production and helper activity in psoriatic patients. Nat Immun 1993; 12: 50-5.
4. Strassmann G, Kambayashi T, Jacob CO, Sredni D. The immunomodulator AS-101 inhibits IL-10 release and augments TNFα and IL-10 release by mouse and human mononuclear phagocytes. Cell Immunol 1997; 176: 180-5.
5. Sredni B, Xu RB, Albeck M et al. The protective role of the immunomodulator AS-101 against chemotherapy-induced alopecia studies on human and animal models. Int J Cancer 1996; 65: 97-103.
6. Olsen E, Hordinsky M, McDonald-Hull S et al. Alopecia areata investigational assessment guidelines. National Alopecia Areata Foundation. J Am Acad Dermatol 1999; 40: 242-6.
7. Valsecchi R, Imberti G, Martino D et al. Alopecia areata and interleukin-2 receptor. Dermatology 1992; 184: 126-8.
8. Zoller M, McElwee KJ, Vitacolonna M, Hoffmann R. The progressive state, in contrast to the stable or regressive state of alopecia areata, is reflected in peripheral blood mononuclear cells. Exp Dermatol 2004; 13: 435-44.
9. Wüthrich B, Joller-Jemelke H, Helfenstein U, Grob PJ. Level of soluble interleukin-2 receptors correlate with the severity of atopic dermatitis. Dermatologica 1990; 181: 92-7.